Demonstrates modularity of Intellia’s in vivo
liver insertion technology to durably restore protein, compared to traditional gene therapy
Single-course administration of genome editing system provides potentially curative approach to AAT deficiency
CAMBRIDGE, Mass., Dec. 12, 2020 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting the first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) in non-human primates (NHPs) following a single administration. Compared to traditional adeno-associated virus (AAV) gene therapy, Intellia’s targeted liver gene insertion technology has the ability to achieve therapeutic levels of protein expression, in a stable and durable manner, after a single course of treatment. The company is presenting these data today at the Alpha-1 Foundation’s 20
Home / Top News / Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
Demonstrates modularity of Intellia’s in vivo
liver insertion technology to durably restore protein, compared to traditional gene therapy
Single-course administration of genome editing system provides potentially curative approach to AAT deficiency
CAMBRIDGE, Mass., Dec. 12, 2020 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting the first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) in non-human primates (NHPs) following a single administration. Compared to traditional adeno-associated virus (AAV) gene therapy, Intellia’s targeted liver gene insertion technology h